You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 19, 2025

Guselkumab - Biologic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


Summary for guselkumab
Tradenames:1
High Confidence Patents:0
Applicants:1
BLAs:1
Suppliers: see list1
Recent Clinical Trials: See clinical trials for guselkumab
Recent Clinical Trials for guselkumab

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Janssen Scientific Affairs, LLCPhase 4
University of PennsylvaniaPhase 3
Janssen Scientific Affairs, LLCPhase 3

See all guselkumab clinical trials

Pharmacology for guselkumab
Mechanism of ActionInterleukin-23 Antagonists
Established Pharmacologic ClassInterleukin-23 Antagonist
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for guselkumab Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for guselkumab Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for guselkumab Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for the Biologic Drug: Guselkumab

Last updated: July 5, 2025

Introduction

Guselkumab, marketed as Tremfya by Janssen Biotech (a Johnson & Johnson subsidiary), has emerged as a key player in the biologic drug market for treating moderate to severe plaque psoriasis and active psoriatic arthritis. Approved by the FDA in 2017, this interleukin-23 inhibitor has demonstrated efficacy in clinical trials, offering patients sustained skin clearance and joint relief. As healthcare costs rise and patient demands evolve, understanding guselkumab's market dynamics and financial trajectory provides critical insights for investors, pharmaceutical executives, and clinicians navigating the competitive biologics landscape.

This analysis delves into current market trends, competitive pressures, and financial performance, drawing on sales data and industry reports to forecast future growth. With the global biologics market projected to expand, guselkumab's role highlights opportunities in targeted therapies amid patent cliffs and biosimilar threats.

Overview of Guselkumab

Guselkumab targets the IL-23 protein, a key driver of inflammatory responses in psoriasis and psoriatic arthritis. Its mechanism inhibits the p19 subunit of IL-23, reducing cytokine production and alleviating symptoms more effectively than some older biologics. Clinical data from trials like VOYAGE 1 and 2 showed that up to 91% of patients achieved at least 90% improvement in the Psoriasis Area and Severity Index (PASI 90) by week 16.

The drug's approval expanded in 2020 to include psoriatic arthritis, broadening its market reach. Janssen has invested heavily in manufacturing and distribution, positioning guselkumab as a premium option in dermatology and rheumatology. Priced at approximately $5,000 per vial in the U.S., it competes on efficacy and safety, with real-world evidence suggesting lower discontinuation rates compared to TNF inhibitors like adalimumab.

Global sales have grown steadily, with Johnson & Johnson's 2023 annual report noting Tremfya's revenue at $4.1 billion, up 22% from the previous year. This growth underscores guselkumab's appeal in a market where patient adherence and long-term outcomes drive prescribing decisions.

Current Market Dynamics

The biologics market for autoimmune diseases is evolving rapidly, influenced by regulatory approvals, patient demographics, and healthcare policies. Guselkumab operates in a segment valued at over $20 billion annually, with psoriasis treatments alone accounting for $10 billion in global sales.

Market Size and Growth

Guselkumab benefits from a psoriasis prevalence rate of about 2-3% in adults worldwide, particularly in regions like North America and Europe where healthcare access is robust. The global psoriasis market is expanding at a compound annual growth rate (CAGR) of 8-10%, driven by an aging population and increasing diagnosis rates. In the U.S., the National Psoriasis Foundation estimates over 8 million cases, fueling demand for advanced biologics.

Emerging markets in Asia-Pacific, such as China and India, present untapped potential, with Janssen expanding access through partnerships and local trials. However, pricing pressures in these regions could temper growth. Data from IQVIA reports indicate that guselkumab captured a 15-20% share of the psoriasis biologic market in 2023, outpacing older drugs like etanercept.

Competitive Landscape

Competition intensifies guselkumab's market dynamics, with rivals like AbbVie's Skyrizi and Eli Lilly's Taltz vying for dominance. Skyrizi, another IL-23 inhibitor, reported $7.8 billion in sales in 2023, highlighting the segment's profitability. Guselkumab differentiates through its dosing schedule—every eight weeks versus some competitors' four-week regimens—enhancing patient convenience and adherence.

Biosimilars pose a looming threat, with the first potential copies of guselkumab's predecessors already entering the market. The European Medicines Agency's approval pathways could introduce generics by 2028, potentially eroding Janssen's market share. Strategic alliances, such as Johnson & Johnson's collaborations with digital health firms for patient monitoring, help maintain guselkumab's edge in a crowded field.

Regulatory environments also shape dynamics. The FDA's expedited review processes, like those under the Biologics License Application, have supported guselkumab's expansions, while the Inflation Reduction Act in the U.S. may cap prices, affecting revenue streams.

Financial Trajectory

Guselkumab's financial performance reflects broader trends in the biologics sector, where innovation drives premium pricing and sustained growth.

Historical Sales Data

Since its launch, guselkumab has delivered impressive revenue figures. Johnson & Johnson's Q4 2023 earnings showed Tremfya sales at $1.1 billion, contributing to the company's immunology portfolio, which exceeded $20 billion annually. This marks a 150% increase from 2019 levels, propelled by expanded indications and market penetration in Europe and Japan.

The drug's profitability stems from high margins in biologics manufacturing, with gross margins reportedly above 80% for Janssen's immunology drugs. Wall Street analysts from firms like Goldman Sachs have praised guselkumab's consistent performance, attributing it to strong prescription trends and minimal safety recalls.

Future Projections

Looking ahead, analysts forecast guselkumab's sales to reach $6-7 billion by 2027, assuming continued market share gains. EvaluatePharma projections estimate a 12% CAGR through 2030, supported by pipeline expansions and potential approvals for new indications, such as Crohn's disease.

Financial risks include patent expirations; guselkumab's core patents extend to 2034, providing a buffer against biosimilars. However, macroeconomic factors like inflation and currency fluctuations could impact global revenues. In a best-case scenario, strategic pricing adjustments and market expansions could yield double-digit growth, positioning guselkumab as a cornerstone of Johnson & Johnson's portfolio.

Key Challenges and Opportunities

Despite its strengths, guselkumab faces challenges like supply chain disruptions, which affected biologics production during the COVID-19 pandemic, and payer negotiations that demand cost-effectiveness data. Opportunities lie in precision medicine, where biomarker testing could tailor guselkumab to specific patient subsets, boosting efficacy and market demand.

Sustainability initiatives, such as reducing the drug's environmental footprint in manufacturing, align with ESG investor priorities, potentially enhancing stock valuations. Johnson & Johnson's R&D investments, totaling $12 billion in 2023, signal ongoing innovation to extend guselkumab's lifecycle.

Conclusion

Guselkumab's market dynamics and financial trajectory underscore its value in the evolving biologics landscape, balancing growth opportunities with competitive pressures. As Janssen navigates regulatory hurdles and expands globally, the drug remains a vital asset for stakeholders seeking reliable returns in healthcare investments.

Key Takeaways

  • Guselkumab has achieved strong sales growth, reaching $4.1 billion in 2023, driven by its efficacy in psoriasis and psoriatic arthritis treatments.
  • The drug holds a 15-20% market share in the psoriasis biologics segment, facing competition from IL-23 inhibitors like Skyrizi.
  • Future revenues could hit $6-7 billion by 2027, supported by patent protections until 2034 and potential new indications.
  • Regulatory and pricing challenges, including biosimilar threats, may influence long-term profitability.
  • Strategic expansions in emerging markets and digital health integrations offer pathways for sustained growth.

Frequently Asked Questions

  1. What makes guselkumab different from other psoriasis treatments?
    Guselkumab specifically targets the IL-23 protein, offering longer dosing intervals and higher efficacy rates compared to TNF inhibitors, as shown in clinical trials.

  2. How has guselkumab's sales performance evolved since its approval?
    Since FDA approval in 2017, sales have grown from under $1 billion annually to $4.1 billion in 2023, reflecting increased adoption and expanded indications.

  3. What factors could impact guselkumab's future market share?
    Biosimilar entries by 2028 and pricing regulations may erode share, while new approvals and market expansions could bolster it.

  4. Is guselkumab profitable for Johnson & Johnson?
    Yes, with gross margins over 80%, guselkumab contributes significantly to the company's immunology profits, exceeding $20 billion in 2023.

  5. How does the global economic climate affect guselkumab's trajectory?
    Inflation and currency volatility could reduce revenues in international markets, but strong demand in developed regions may offset these risks.

Sources

  1. Johnson & Johnson. (2023). Annual Report. Retrieved from Johnson & Johnson investor relations.
  2. IQVIA Institute. (2023). Global Use of Medicines Report. Retrieved from IQVIA official website.
  3. EvaluatePharma. (2023). World Preview 2024, Outlook to 2030. Retrieved from EvaluatePharma database.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.